htl0039732
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 13, 2023 (NCT05944237)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Colorectal Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 1/Phase 2
- Kidney Neoplasms · Phase 1/Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Mesothelioma, Malignant · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Pheochromocytoma · Phase 1/Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 1/Phase 2
- Sarcoma · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
Mechanism of action
- Prostanoid EP3 receptorINHIBITOR
PTGER3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05944237 | Phase 1/Phase 2 (Phase 2) | Jul 13, 2023 | Cancer Research UK, Heptares Therapeutics Limited |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cancer Research UK | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Heptares Therapeutics Limited | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1